Syngene expanded its long-running strategic relationship with Bristol Myers Squibb through 2035, extending integrated drug development and manufacturing services across the full pipeline lifecycle. The extended agreement covers discovery support, translational sciences, pharmaceutical development, manufacturing, and clinical trial and data/IT services. The partnership traces back decades, including the establishment of the Biocon Bristol Myers Squibb R&D center, which became a core site for BMS work. Syngene and BMS framed the extension as a commitment to long-horizon investment in capabilities and infrastructure. For the CRO/CDMO ecosystem, the deal highlights how long-term integrated service models remain a strategic preference for large sponsors seeking continuity from early-stage development through commercialization.